×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EQ – equillium, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EQ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
5/6
08:33 am
eq
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists [Yahoo! Finance]
Low
Report
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists [Yahoo! Finance]
5/6
08:00 am
eq
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
Medium
Report
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
5/1
08:12 am
eq
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 [Yahoo! Finance]
High
Report
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 [Yahoo! Finance]
5/1
08:00 am
eq
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
Medium
Report
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
4/24
09:00 am
eq
Equillium Announces Feedback from the U.S. Food and Drug Administration
High
Report
Equillium Announces Feedback from the U.S. Food and Drug Administration
3/29
07:22 am
eq
Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
3/28
08:20 am
eq
Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.
High
Report
Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.
3/27
07:00 am
eq
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
High
Report
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
6/13
04:06 pm
eq
Form 8-K Equillium, Inc. For: Jun 12
Medium
Report
Form 8-K Equillium, Inc. For: Jun 12
6/12
04:19 pm
eq
Form 144 Equillium, Inc. Filed by: Keyes Jason A
Medium
Report
Form 144 Equillium, Inc. Filed by: Keyes Jason A
5/23
01:51 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: Colabuono Peter
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: Colabuono Peter
5/23
01:48 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: DEMSKI MARTHA J
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: DEMSKI MARTHA J
5/23
01:45 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: Pruzanski Mark
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: Pruzanski Mark
5/23
01:43 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: McDermott Charles Douglas
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: McDermott Charles Douglas
5/23
01:41 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: Troupin Barbara
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: Troupin Barbara
5/23
01:38 pm
eq
Form 4 Equillium, Inc. For: May 21 Filed by: MANIAN BALA S
Medium
Report
Form 4 Equillium, Inc. For: May 21 Filed by: MANIAN BALA S
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
33.1%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
TOP News Decliners
12/31
Equillium (NYSE: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
-19.3%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: